Saturday, September 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 3, 2025

BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung

View original at globenewswire.com
BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung BioNTech treibt Onkologiestrategie mit dem Fokus auf zwei tumorübergreifende (Pan-Tumor)-Programme sowie Kombinationsansätze weiter voran, um das gesamte Spektrum von Krebserkrankungen vom frühen bis zum späten S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trastuzumab Pamirtecan BLA filing planned for 2026 pending FDA feedback

    80% confidence

  • 2025 R&D costs expected to be €2,000-2,200M, reduced from previous guidance of €2,600-2,800M

    80% confidence

  • BioNTech expects no positive net income for FY 2025

    80% confidence

  • Autogene Cevumeran showed strong durable immune responses up to 1.5 years post-treatment with broad immune response correlated with extended PFS

    80% confidence

  • BNT111 demonstrated deep durable antitumor responses with statistically significant improvement in ORR vs historical control

    80% confidence

  • 2025 SG&A costs expected to be €550-650M, reduced from previous guidance of €650-750M

    80% confidence

  • Pumitamig showed encouraging anti-tumor activity, positive PFS trend, controlled safety profile, and low discontinuation rate in ES-SCLC Phase 2 trial

    80% confidence

  • 2025 CapEx expected to be €200-250M, reduced from previous guidance of €250-350M

    80% confidence

  • 2025 revenue guidance is €2,600-2,800M

    80% confidence

  • ROSETTA Breast-01 Phase 3 trial for TNBC will start by end of 2025

    80% confidence

Data points we hold from this source

BioNTech SE · outstanding shares240455450 shares
BioNTech SE · r and d costs564.8 million_EUR
BioNTech SE · sg and a costs148.5 million_EUR
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung — Source | Via News | Via News